Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer

British Journal of Cancer

Volumn 89, Issue 5, 2003, Pages 787-794

  Kloft, C ^a   Siegert, W ^b   Jaehde, U ^a,c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Dose individualisation; Germ cell tumour; High dose carboplatin; High dose chemotherapy; Population pharmacokinetics

Indexed keywords

ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; CARBOPLATIN; CISPLATIN; CREATININE; ETOPOSIDE; IFOSFAMIDE; MESNA; PACLITAXEL; THIOTEPA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BODY HEIGHT; BODY SURFACE; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; COVARIANCE; CREATININE CLEARANCE; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; EXTRACELLULAR SPACE; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; HUMAN; HYPERURICEMIA; INDIVIDUALIZATION; INFECTION; MODEL; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; POPULATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TOXICITY; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METABOLIC CLEARANCE RATE; NEOPLASMS, GERM CELL AND EMBRYONAL;

EID: 0141730421     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601215     Document Type: Article

References (36)

1. Baker SD, Grochow LB, Donehower RC (1995) Should anticancer drug doses be adjusted in the obese patient? J Natl Cancer Inst 87: 333-334
2. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24: 153-172
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
4. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87: 573-580
5. Chatelut E, Pivot X, Otto J, Chevreau C, Thyss A, Renee N, Milano G, Canal P (2000) A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 36: 264-269
6. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
7. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, Nooter K, Stoter G, Sparreboom A (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19: 3733-3739
8. Draper N, Smith H (1966) Applied Regression Analysis, Chapter 6. New York: John Wiley & Sons
9. DuBois D, DuBois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17: 863-871
10. Egorin MJ, Jodrell DI (1992) Utility of individualized carboplatin dosing alone and in combination regimens. Semin Oncol 19: 132-138
11. Gehan EA, George SL (1970) Estimation of human body surface area from height and weight. Cancer Chemother Rep 54: 225-235
12. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422
13. Gomeni R, Pineau G, Mentre F (1994) Population kinetics and conditional assessment of the optimal dosage regimen using the P-Pharm software package. Anticancer Res 14: 2321-2326
14. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Haper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepperd J (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 16: 2426-2434
15. Grochow LB, Baraldi C, Noe D (1990) Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82: 323-325
16. Huitema AD, Spaander M, Mathjt RA, Tibben MM, Holtkamp MJ, Beijnen JH, Rodenhuis S (2002) Relationship between exposure and toxicity in high-dose chemotherapy with cyclophophamide, thiotepa and carboplatin. Ann Oncol 13: 374-384
17. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-528
18. Kloft C, Appelius H, Siegert W, Schunack W, Jaehde U (1999) Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther Drug Monit 21: 631-637
19. Kloft C, Siegert W, Beyer J, Jaehde U (2002) Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance. J Clin Pharmacol 42: 762-773
20. Loos WJ, Gelderblom H, Sparreboom A, Verweij J, de Jonge MJ (2000) Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 6: 2685-2689
21. Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A (2002) Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 20: 81-87
22. McGuire WP (1979) Educational Book of the Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology, Dallas, 1994. In Modification: WHO Handbook for Reporting Results of Cancer Treatment, Vol. 48, p. 204. Geneva: World Health Organisation
23. Mitchell D, Strydom NB, van Graan CH, van der Walt WH (1971) Human surface area: comparison of the Du Bois formula with direct photometric measurement. Pflugers Arch 325: 188-190
24. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18: 1173-1180
25. Newell DR, Pearson AD, Balmanno K, Price L, Wyllie RA, Keir M, Calvert AH, Lewis IJ, Pinkerton CR, Stevens MC (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol 11: 2314-2323
26. Newell DR, Siddik ZH, Gumbrell LA, Boxall FE, Gore ME, Smith IE, Calvert AH (1987) Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 23: 1399-1405
27. Ratain MJ (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16: 2297-2298
28. Reilly JJ, Workman P (1994) Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research. Cancer Chemother Pharmacol 34: 3-13
29. Rodenhuis S, de Wit R, de Mulder PH, Keizer HJ, Sleijfer DT, Lalisang RI, Bakker PJ, Mandjes I, Kooi M, de Vries EG (1999) A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10: 1467-1473
30. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei III E, Henner WD (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7: 651-661
31. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-512
32. Siegert W, Rick O, Beyer J (1998) High-dose chemotherapy with autologous stem-cell support in poor-risk germ cell tumors. Ann Hematol 76: 183-188
33. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH (1996a) Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 37: 266-270
34. van Warmerdam LJ, Rodenhuis S, van der Wall E, Maes RA, Beijnen JH (1996b) Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 73: 979-984
35. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84: 452-459
36. Wright JE, Elias A, Tretyakov O, Holden S, Andersen J, Wheeler C, Schwartz G, Antman K, Rosowsky A, Frel III E (1995) High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol 36: 345-351